Slide
Securing
Connections
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest Presentations
January 8, 2024
Press Releases
April 11, 2024
Events & Presentations
December 6, 2023 from 12:15 PM to 12:45 PM EST
November 16, 2023 from 1:00 PM to 1:25 PM GMT
October 12, 2023 at 8:30 AM EDT